S&P 500   2,749.98 (+3.41%)
DOW   23,433.57 (+3.44%)
QQQ   200.57 (+2.12%)
AAPL   266.07 (+2.56%)
FB   174.28 (+3.23%)
MSFT   165.13 (+1.00%)
GOOGL   1,207.00 (+2.07%)
AMZN   2,043.00 (+1.56%)
CGC   14.83 (+2.28%)
NVDA   266.95 (+3.06%)
BABA   195.98 (-1.02%)
MU   48.29 (+3.76%)
GE   7.30 (+3.84%)
TSLA   548.84 (+0.62%)
AMD   48.79 (+2.59%)
T   29.89 (-0.63%)
ACB   0.85 (+6.23%)
F   5.03 (+6.79%)
NFLX   371.12 (-0.31%)
BAC   23.45 (+5.92%)
GILD   74.99 (+0.43%)
DIS   101.07 (-0.17%)
PRI   97.51 (+10.73%)
S&P 500   2,749.98 (+3.41%)
DOW   23,433.57 (+3.44%)
QQQ   200.57 (+2.12%)
AAPL   266.07 (+2.56%)
FB   174.28 (+3.23%)
MSFT   165.13 (+1.00%)
GOOGL   1,207.00 (+2.07%)
AMZN   2,043.00 (+1.56%)
CGC   14.83 (+2.28%)
NVDA   266.95 (+3.06%)
BABA   195.98 (-1.02%)
MU   48.29 (+3.76%)
GE   7.30 (+3.84%)
TSLA   548.84 (+0.62%)
AMD   48.79 (+2.59%)
T   29.89 (-0.63%)
ACB   0.85 (+6.23%)
F   5.03 (+6.79%)
NFLX   371.12 (-0.31%)
BAC   23.45 (+5.92%)
GILD   74.99 (+0.43%)
DIS   101.07 (-0.17%)
PRI   97.51 (+10.73%)
S&P 500   2,749.98 (+3.41%)
DOW   23,433.57 (+3.44%)
QQQ   200.57 (+2.12%)
AAPL   266.07 (+2.56%)
FB   174.28 (+3.23%)
MSFT   165.13 (+1.00%)
GOOGL   1,207.00 (+2.07%)
AMZN   2,043.00 (+1.56%)
CGC   14.83 (+2.28%)
NVDA   266.95 (+3.06%)
BABA   195.98 (-1.02%)
MU   48.29 (+3.76%)
GE   7.30 (+3.84%)
TSLA   548.84 (+0.62%)
AMD   48.79 (+2.59%)
T   29.89 (-0.63%)
ACB   0.85 (+6.23%)
F   5.03 (+6.79%)
NFLX   371.12 (-0.31%)
BAC   23.45 (+5.92%)
GILD   74.99 (+0.43%)
DIS   101.07 (-0.17%)
PRI   97.51 (+10.73%)
S&P 500   2,749.98 (+3.41%)
DOW   23,433.57 (+3.44%)
QQQ   200.57 (+2.12%)
AAPL   266.07 (+2.56%)
FB   174.28 (+3.23%)
MSFT   165.13 (+1.00%)
GOOGL   1,207.00 (+2.07%)
AMZN   2,043.00 (+1.56%)
CGC   14.83 (+2.28%)
NVDA   266.95 (+3.06%)
BABA   195.98 (-1.02%)
MU   48.29 (+3.76%)
GE   7.30 (+3.84%)
TSLA   548.84 (+0.62%)
AMD   48.79 (+2.59%)
T   29.89 (-0.63%)
ACB   0.85 (+6.23%)
F   5.03 (+6.79%)
NFLX   371.12 (-0.31%)
BAC   23.45 (+5.92%)
GILD   74.99 (+0.43%)
DIS   101.07 (-0.17%)
PRI   97.51 (+10.73%)
Log in

NASDAQ:BVXVBIONDVAX PHARMA/S Stock Price, Forecast & News

$7.40
-0.28 (-3.65 %)
(As of 04/8/2020 04:00 PM ET)
Add
Compare
Today's Range
$7.40
Now: $7.40
$7.95
50-Day Range
$5.36
MA: $7.54
$9.15
52-Week Range
$5.20
Now: $7.40
$13.50
Volume12,900 shs
Average Volume41,611 shs
Market Capitalization$48.37 million
P/E RatioN/A
Dividend YieldN/A
Beta1.33
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Ness Ziona, Israel.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BVXV
CUSIPN/A
Phone972-8930-2529

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($1.27) per share

Profitability

Net Income$-23,410,000.00

Miscellaneous

Employees14
Market Cap$48.37 million
Next Earnings Date6/4/2020 (Estimated)
OptionableNot Optionable

Receive BVXV News and Ratings via Email

Sign-up to receive the latest news and ratings for BVXV and its competitors with MarketBeat's FREE daily newsletter.


BIONDVAX PHARMA/S (NASDAQ:BVXV) Frequently Asked Questions

How has BIONDVAX PHARMA/S's stock been impacted by COVID-19 (Coronavirus)?

BIONDVAX PHARMA/S's stock was trading at $6.5350 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BVXV shares have increased by 13.2% and is now trading at $7.40. View which stocks have been most impacted by Coronavirus.

When is BIONDVAX PHARMA/S's next earnings date?

BIONDVAX PHARMA/S is scheduled to release its next quarterly earnings announcement on Thursday, June 4th 2020. View our earnings forecast for BIONDVAX PHARMA/S.

Has BIONDVAX PHARMA/S been receiving favorable news coverage?

Media headlines about BVXV stock have trended very negative this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BIONDVAX PHARMA/S earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutBIONDVAX PHARMA/S.

Who are some of BIONDVAX PHARMA/S's key competitors?

What other stocks do shareholders of BIONDVAX PHARMA/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BIONDVAX PHARMA/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pluristem Therapeutics (PSTI), Exelixis (EXEL), BIOLINERX LTD/S (BLRX), Agilent Technologies (A), Enterprise Products Partners (EPD), AT&T (T), NovaBay Pharmaceuticals (NBY) and Akari Therapeutics (AKTX).

Who are BIONDVAX PHARMA/S's key executives?

BIONDVAX PHARMA/S's management team includes the following people:
  • Dr. Ron Babecoff, Co-Founder, CEO, Pres & Director (Age 57)
  • Mr. Uri Ben-Or CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 49)
  • Dr. Tamar Ben Yedidia, Chief Scientific Officer (Age 55)
  • Dr. Shimon Hassin, Chief Operating Officer
  • Mr. Elad Mark, Head of Site & Process Devel.

When did BIONDVAX PHARMA/S IPO?

(BVXV) raised $10 million in an initial public offering on Tuesday, May 12th 2015. The company issued 1,400,000 shares at a price of $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO.

What is BIONDVAX PHARMA/S's stock symbol?

BIONDVAX PHARMA/S trades on the NASDAQ under the ticker symbol "BVXV."

How do I buy shares of BIONDVAX PHARMA/S?

Shares of BVXV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BIONDVAX PHARMA/S's stock price today?

One share of BVXV stock can currently be purchased for approximately $7.40.

How big of a company is BIONDVAX PHARMA/S?

BIONDVAX PHARMA/S has a market capitalization of $48.37 million. The company earns $-23,410,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis. BIONDVAX PHARMA/S employs 14 workers across the globe. View additional information about BIONDVAX PHARMA/S.

What is BIONDVAX PHARMA/S's official website?

The official website for BIONDVAX PHARMA/S is http://www.biondvax.com/.

How can I contact BIONDVAX PHARMA/S?

BIONDVAX PHARMA/S's mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The company can be reached via phone at 972-8930-2529 or via email at [email protected]

This page was last updated on 4/8/2020 by MarketBeat.com Staff

Featured Article: What are retained earnings?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel